Genetic Immunology Laboratory, HUMIGEN, The Institute for Genetic Immunology, 2439 Kuser Road, Hamilton, NJ 08690-3303, USA.
Cytokine Growth Factor Rev. 2010 Oct;21(5):345-52. doi: 10.1016/j.cytogfr.2010.08.005.
First reported in 1999, IL-19 remains a mystery in many ways. Despite appearing in many genome scans and candidate gene studies, and having been searched for specifically as part of the IL-10 family, its function is still to be defined. Nonetheless, a pattern of Th2 promotion is coalescing from this nebulous body of work, supported by increasing evidence for a role in asthma. Similarly, a clear but less intuitive role as a subtle immunomodulator is emerging in psoriasis and chronic inflammatory disorders in general. Indeed, several human diseases and their animal models have highlighted a role for IL-19. Key questions remain, relating to the nature of its receptor, its function (if any) on leukocytes and how its effects are distinguished by the cell from those of IL-20 and IL-24. In this review, I shall attempt to bring together a summary of the known work - disparate as it may be - as well as presenting a picture of these two important clinical disorders and the potential involvement of this somewhat enigmatic cytokine.
IL-19 于 1999 年首次报道,在许多方面仍然是一个谜。尽管它出现在许多基因组扫描和候选基因研究中,并作为 IL-10 家族的一部分被专门寻找,但它的功能仍有待确定。尽管如此,从这些模糊的研究中,Th2 促进的模式正在汇聚,越来越多的证据支持其在哮喘中的作用。同样,在银屑病和一般慢性炎症性疾病中,它作为一种微妙的免疫调节剂的作用也越来越明显,但不那么直观。事实上,几种人类疾病及其动物模型突出了 IL-19 的作用。关键问题仍然存在,涉及到其受体的性质、在白细胞上的功能(如果有的话)以及细胞如何将其作用与 IL-20 和 IL-24 区分开来。在这篇综述中,我将尝试总结已知的工作——尽管可能各不相同——并呈现这两种重要的临床疾病的图片,以及这种有些神秘的细胞因子的潜在参与。